Previous 10 | Next 10 |
CAMBRIDGE, Mass., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced the appointment of biopharmaceutical industry veteran Juan Andres t...
CAMBRIDGE, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that management will present a corporate overview at the Stifel 201...
Evelo Biosciences, Inc. (EVLO) Q3 2019 Earnings Conference Call November 05, 2019, 08:30 ET Company Participants Jessica Cotrone - IR Balkrishan Gill - President, CEO & Director Duncan McHale - Chief Medical Officer Mark Bodmer - Chief Scientific Officer & President, Re...
CAMBRIDGE, Mass., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that preclinical data from its oncology program, EDP1503, will be present...
Evelo Biosciences (NASDAQ: EVLO ): Q3 GAAP EPS of -$0.67 misses by $0.08 . More news on: Evelo Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
--EDP1815 was Well Tolerated with No Overall Difference Reported from Placebo-- --Reduction in Mean Lesion Severity Score (LSS) at 28 Days Consistent with Low Dose Cohort-- -- Dose Response Trends Observed in LSS and PASI at Day 42-- --Phase 2 Study Initiation Expected in Early 2020-...
--EDP1815 was Well Tolerated with No Overall Difference Reported from Placebo-- --Reduction in Mean Lesion Severity Score (LSS) at 28 Days Consistent between High and Low Dose Cohort-- -- Dose Response Trends Observed in LSS and PASI at Day 42-- --EDP1815 Phase 2 Study Initiation Expected i...
CAMBRIDGE, Mass., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences (NASDAQ:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that it will host a conference call and live webcast at 8:30 A.M. ET on T...
CAMBRIDGE, Mass,, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing orally delivered, systemically acting biologics, today announced that management will present a corporate overview at the 2019 Cantor Global Healthca...
CAMBRIDGE, Mass., Sept. 20, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing orally delivered, systemically acting biologics, today announced that it will host a key opinion leader symposium on the unmet need in mild to moder...
News, Short Squeeze, Breakout and More Instantly...
Evelo Biosciences Inc. Company Name:
EVLO Stock Symbol:
OTCMKTS Market:
Evelo Biosciences Inc. Website:
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...